Johnson & Johnson: Virus Diseases trials

The registry lists 26 Virus Diseases studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 19 have results posted.

Phase 1 4Phase 2 19Phase 3 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus InfectionTerminatedNCT05005507Phase 2Results posted
• A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT04978337Phase 2Results posted
• A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedNCT04667104Phase 2Results posted
• A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus InfectionCompletedNCT04585789Phase 2Results posted
• A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedNCT04129554Phase 2Results posted
• A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract DiseaseCompletedNCT04068792Phase 2Results posted
• Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)TerminatedNCT04056611Phase 2Results posted
• A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus InfectionCompletedNCT03982186Phase 2Results posted
• A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in InfantsCompletedNCT03929757Phase 2Results posted
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus InfectionTerminatedNCT03656510Phase 2Results posted
• An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus InfectionCompletedNCT03361956Phase 2Results posted
• An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old AdultsCompletedNCT03334695Phase 2Results posted
• A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial VirusTerminatedNCT03333317Phase 2Results posted
• A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus InfectionCompletedNCT03332459Phase 2Results posted
• A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naiveCompletedNCT02993250Phase 2Results posted
• Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial VirusTerminatedNCT02935673Phase 2Results posted
• Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-FiloCompletedNCT02509494Phase 3Results posted
• A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy AdultsCompletedNCT02416453Phase 2Results posted
• Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus InfectionCompletedNCT02250807Phase 3Results posted
• A Study to Investigate Acute Respiratory Virus Infections in Participants at High Risk for Severe IllnessCompletedNCT05661604
• A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus InfectionCompletedNCT05242445Phase 1
• A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus InfectionCompletedNCT05123599Phase 1
• A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus InfectionTerminatedNCT03253471Phase 1
• A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) InfectionTerminatedNCT02593851Phase 1
• Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection.CompletedNCT02387606Phase 2
• A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge ModelCompletedNCT02094365Phase 2